定量分析两种治疗方案与危险指数对慢性髓系白血病临床缓解率的影响  

Quantitative analysis of Sokal's risk index in relation to2therapy protocols:their respective impact on clinical remission of chronic myeloid leukemia

作　　者：杜庆锋[1] 刘晓力[1] 刘启发[1] 李荣[1] 陈琪[1] 周淑芸[1] 

机构地区：[1]第一军医大学南方医院血液科,广东广州510515

出　　处：《第一军医大学学报》2002年第8期729-730,共2页Journal of First Military Medical University

基　　金：广东省自然科学基金(970833)

摘　　要：目的定量分析两种治疗方案与危险指数对慢性髓系白血病(CML)临床缓解率的影响。方法按治疗方案与Sokal危险指数分别进行分组,定量分析三尖杉酯碱联合阿糖胞苷(HA)与羟基脲(Hu)二种治疗方案和病人初诊时所处的危险度对慢性期CML患者所获临床疗效的影响。结果尽管HA方案治疗初诊CML慢性期患者的近期疗效优于Hu,但它并不能延长病人的慢性期维持时间(DCP);而且病人的危险指数对完全缓解率(CR)、获CR所需时间及DCP的影响均远超出治疗方案的作用。结论HA方案不能延长病人的DCP,不宜作为初诊CML慢性期患者的一线治疗方案;按危险指数将病人作出合适分层,有利于治疗方案的合理选择及科学评价。Objective To quantitatively evaluate the impact of Sokal's risk index and that of 2 therapy protocols on the clinical outcome of patients with chronic myeloid leukemia (CML). Methods With the assistance of Access 2000 database of CML, 94 patients with CML were grouped on the basis of either different therapy protocols ulilizing harringtonine plus Ara-C (HA) vs hydroxyurea (Hu) or Sokal scores, and the impact of therapy protocol and risk profile were quantitatively evaluated respectively. Result Treatment protocol utilizing HA was incapable of lengthening the duration of chronic phase (DCP) of CML, regardless of its better short-term effect than that of Hu. The impact of risk profile of the patients on clinical remission rate and DCP was more significant than that of the therapy protocols. Conclusion HA should not be used as the first-line protocol in the treatment of CML patients in chronic phase who have not received any previous medical intervention. Patients should be categorized according to the risk profile for choosing appropriate treatment protocol and making better clinical judgement.

关 键 词：三尖杉酯碱 羟基脲 Sokal危险指数 慢性髓系白血病 治疗 

分 类 号：R733.72[医药卫生—肿瘤]